Riskpilot← Back to searchSign inGet full accessSalipro Biotech AB
ABActiveOrg 5569420200Teknikringen 38 AResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20138 employees
Revenue 2024
SEK 6,6M
+10% vs 2023
EBITDA margin
-58.2%
-3% vs 2023
Equity ratio
86.5%
Financial strength
Net profit 2024
SEK -4,6M
-7% vs 2023
| Revenue | SEK 6,6M | +10% |
| EBITDA | SEK -3,8M | -3% |
| Net profit | SEK -4,6M | -7% |
| Total assets | SEK 10,8M | -31% |
| Equity | SEK 9,3M | -33% |
| Employees | 8 | — |
Legal name
Salipro Biotech AB
Org number
5569420200
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
10 september 2013
Share capital
SEK 69 310
Employees
8 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företagets verksamhet är forskning, utveckling och försäljning av produkter bestående av nanopartiklar som ökar lösligheten av hydrofoba ämnen med användningsområden inom t.ex. läkemedelsutveckling, vaccinationer, kosmetika och därmed förenlig verksamhet.
Address
Teknikringen 38 A
Phone
+46700520421
Email
jens.frauenfeld@salipro.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 535 | 4 509 | 7 468 | 5 968 | 6 571 |
| Staff expenses | — | — | −6 143 | −7 039 | −6 740 |
| EBITDA | −1 412 | −1 463 | −1 847 | −3 708 | −3 827 |
| Depreciation & amort. | −440 | −478 | −587 | −725 | −806 |
| EBIT | −1 852 | −1 941 | −2 434 | −4 434 | −4 634 |
| Net financials | — | — | 28 | 170 | 82 |
| Profit before tax | −1 852 | −1 941 | −2 406 | −4 264 | −4 552 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −1 852 | −1 941 | −2 406 | −4 264 | −4 552 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 8 795 | 21 967 | 19 625 | 15 620 | 10 796 |
| Equity | 7 500 | 20 557 | 18 151 | 13 887 | 9 335 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 1 295 | 1 410 | 1 474 | 1 733 | 1 461 |
| Total debt | 1 295 | 1 410 | 1 474 | 1 733 | 1 461 |
EBITDA margin
-58.2%
This company
15.8%
Market median
-468% vs market
20202024
Equity ratio
86.5%
This company
38.2%
Market median
+126% vs market
20202024
Return on equity
-48.8%
This company
18.4%
Market median
-365% vs market
20202024
Net profit margin
-69.3%
This company
8.1%
Market median
-956% vs market
20202024
Asset turnover
0.61×
This company
1.12×
Market median
-46% vs market
20202024
Debt / equity
0.16×
This company
0.62×
Market median
+74% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
ME Chief Auditor | Chief Auditor | 2022 |
JF Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (2) | ||
IM Chief Auditor | Chief Auditor | 2022 – 2024 |
BS Chief Auditor | Chief Auditor | 2020 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 62% | 62% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Frauenfeld Holding AB
Salipro Biotech AB Board members of Salipro Biotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Erzsébet Magdalena Lennmark | Chief Auditor | 0 companies |
| Jens Frauenfeld | Chief Executive Officer | 0 companies |
| Ida Maria Brandt | Chief Auditor | 0 companies |
| Björn Sture Bernhard Peters Ohlsson | Chief Auditor | 0 companies |
| Christine Becker | Deputy Board Member | 0 companies |